Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1210 versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab
NL-OMON50494Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing ALXN1210 with Soliris (2 arms). Primary endpoint: Hemolysis as directly measured by lactate dehydrogenase percent change. Started Aug 2017; status: active, not recruiting.
02
Drugs
ravulizumabeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON50494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50494.